European product revenues threatened by IP policy amendment

Legislation to boost European biosimilars and generics sales could cut into revenues of patent-protected drugs

As European inventors at universities and small biotechs struggle with new patent policies that will make it harder to protect life science inventions, at the other end of the spectrum, large commercialization-stage biopharmas in Europe are facing their own IP issues, including a policy change that will cut into revenues from patent-protected products.

By the end of the year, the European Patent Office plans to enact a proposal to streamline review of patent applications

Read the full 742 word article

User Sign In